Sai Parenterals Limited H1 FY27 Profit Beats FY26 as Deals Close
Key highlights
- Sai Parenterals reported H1 FY27 consolidated revenue of ₹373.6 crore, about 98% of FY26 full-year revenue of ₹381 crore.
- H1 FY27 PAT was ₹18.4 crore, above Sai Parenterals' FY26 full-year PAT of ₹14.3 crore.
- Sai Parenterals completed a 60% acquisition of Saicriti Pharma, making it a subsidiary.
- The board approved buying SP Analytics' remaining 25% stake, with completion listed by December 31, 2026.
powered by IRIS

Sai Parenterals Limited reported H1 FY27 profit after tax of ₹18.4 crore, exceeding its FY26 full-year PAT of ₹14.3 crore, while completing the acquisition of a 60% stake in Saicriti Pharma and approving the purchase of SP Analytics' remaining 25% stake. The developments combine a sharp improvement in reported earnings with changes to the company's subsidiary structure.
Know Sai Parenterals inside out
Results, valuation, peers and who's buying, in one view.
What did Sai Parenterals report for H1 FY27?
Sai Parenterals reported consolidated revenue of ₹373.6 crore for the half year ended September 30, 2026, or H1 FY27, and PAT of ₹18.4 crore. H1 revenue was about 98% of the company's reported FY26 full-year revenue of ₹381 crore, while the half-year profit was higher than FY26 PAT of ₹14.3 crore.
The comparison indicates that the company had reached close to its previous full-year revenue level within the first six months of FY27. Its H1 PAT was ₹4.1 crore higher than the FY26 annual figure. The disclosed figures provide a useful measure of the scale of business reported during the period, although they do not by themselves explain the contribution from individual products, businesses or acquired entities.
The board considered and approved financial results for the period ended September 30, 2026 at its meeting on November 1, 2026. Sai Parenterals scheduled an earnings conference call for November 2, 2026 at 2:00 PM IST to discuss the quarterly and half-year operational and financial performance with investors and analysts.
Which acquisitions did the board complete or approve?
Sai Parenterals completed the acquisition of a 60% stake in Saicriti Pharma, making the business a subsidiary. The company also disclosed completion of 60% acquisitions in Saicriti Pharma and Sai Prathyak Laboratories as part of its strategic updates accompanying the H1 FY27 results.
Separately, the board approved the purchase of the remaining 25% shareholding in SP Analytics Private Limited. Sai Parenterals already owned 75% of SP Analytics, and the proposed transaction would make the testing and analysis business a wholly owned subsidiary.
The filing identifies SP Analytics' promoters as promoters of Sai Parenterals, making the transaction a related-party acquisition. It states that the consideration will be paid in cash and describes the proposed acquisition value as ₹25,000 at face value. The target's stated business is testing, analysis and examination of pharmaceuticals, medicines, drugs and other materials.
The filing lists December 31, 2026 as the expected completion date for the SP Analytics transaction. It also records that SP Analytics was incorporated on November 16, 2023 and operates in India. No turnover figures for the target for FY24, FY25 or FY26 were disclosed in the supplied information.
Got a follow-up? Ask IRIS
Why are the transactions important to Sai Parenterals' operations?
The transactions are important because they expand the group structure across manufacturing, capacity, research and pharmaceutical testing activities. The company said that its Unit III expansion had raised capacity to 155 million units a month, while the Saicriti Pharma and Sai Prathyak Laboratories acquisitions were intended to support capacity and R&D.
Sai Parenterals had earlier proposed using ₹101.857 crore of unutilised IPO proceeds to acquire 60% stakes in Saicriti Pharma and Sai Prathyak Laboratories. The company had said the redirection of funds would support manufacturing capabilities and research and development, subject at that stage to definitive agreements, due diligence and statutory approvals.
The company also maintained FY27 revenue guidance of ₹750 crore in the supplied disclosures. Against that target, H1 FY27 consolidated revenue of ₹373.6 crore represents nearly half of the stated annual guidance. The disclosed H1 financial performance and progress on acquisitions are therefore relevant to investors assessing the company's ability to execute its expansion plan.
How does full ownership of SP Analytics change the group structure?
Full ownership of SP Analytics would simplify Sai Parenterals' control over a business that is already a 75%-owned subsidiary. Once the remaining stake is acquired, the company would not have an outside minority shareholder in that subsidiary.
The transaction is relatively small in stated consideration compared with the company's revenue figures, but its relevance lies in the ownership structure and the nature of the subsidiary's work. Pharmaceutical testing and analysis can support quality-control and examination activities within a broader pharma group, although the filing does not quantify any operational or financial benefit expected from the acquisition.
For investors, the key disclosed issues are the related-party nature of the deal, the cash-payment structure and the targeted completion date. The supplied filing does not provide an independent valuation, future revenue contribution, profit contribution or separate financial results for SP Analytics, so those items cannot be assessed from the available information.
How did the company reach this stage of expansion?
Sai Parenterals was founded in 2001, while its current operating structure was reshaped after promoters took full control in 2016. In late 2025, it acquired a controlling stake in Australia's Noumed Pharmaceuticals, which gave it a route to pharmacy markets in Australia and New Zealand, according to the supplied background.
The FY27 strategy has combined organic capacity additions with acquisitions. The earlier board approval to redirect IPO proceeds toward stakes in Saicriti Pharma and Sai Prathyak Laboratories framed the purchases as measures to expand capacity and R&D. The November 1 board actions show that the Saicriti Pharma acquisition has since been completed and that the company is pursuing complete ownership of SP Analytics.
Conclusion
The H1 FY27 disclosures show Sai Parenterals combining materially higher reported profit with a broader subsidiary portfolio. Consolidated revenue of ₹373.6 crore was close to FY26's full-year ₹381 crore, while H1 PAT of ₹18.4 crore was above the prior year's annual PAT. The completed Saicriti Pharma stake acquisition and proposed SP Analytics buyout add structural changes alongside the financial results.
Investors will watch for the scheduled completion of the SP Analytics purchase by December 31, 2026, details from the November 2 earnings call, and progress toward the company's FY27 revenue guidance of ₹750 crore. Further disclosures on the financial contribution of acquired businesses, integration costs and capacity utilisation would provide additional clarity on the expansion programme.


